This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



June 26, 2025

Company name:Kaneka CorporationRepresentative:Kazuhiko Fujii, President,
Representative DirectorListing:Prime Market, Tokyo Stock ExchangeSecurities code:4118Inquiries:Atsuya Inoguchi, Head of Investors
Relations Department
(Tel 03 – 5574 - 8090)

(Correction) Notice Concerning Partial Correction of "Financial Summary for the Fiscal Year Ended March 31, 2025"

Kaneka Corporation hereby announces that there was an error in a part of the "Financial Summary for the Fiscal Year Ended March 31, 2025," disclosed on May 15, 2025, as detailed below. Revised materials reflecting the corrected information have been posted on our corporate website (https://www.kaneka.co.jp/en/ir/library/briefs/).

Notice


I. Details of Correction Corrections are outlined in red. [Before Correction]

Page 11

Investm	ent, Deprecia	tion, R&D	Expenses			KOUEK
			(Billions of yen)			
			FY2023	FY2024	Difference	
	Capital investment Depreciation and amortization		69.2	53.1	<mark>(</mark> 16.1)	
			40.5	43.6	3.1	
	R&D expenses		35.4	39.8	4.4	
	R&D expense	es to net sales	4.6%	4.9%		
	●Main capital investr		- Y2024 Results			
	Introduction of co-generation system at Takasago					
	 Construction of new plant for blood purification devices and catheter in Hokkaido (Tomatoh Manufacturing Site) 					
	Increased production capacity in Kaneka Belgium N.V., MS					

[After Correction]

Page 11



The revision is due to a misclassification between R&D expenses and selling expenses within SG&A. This has no impact on operating income or subsequent profit figures, nor does it affect the profit and loss results by business segment.